Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

241.70CHF
11:29am EST
Change (% chg)

CHF0.00 (+0.00%)
Prev Close
CHF241.70
Open
CHF240.60
Day's High
CHF242.40
Day's Low
CHF240.60
Volume
1,444,414
Avg. Vol
1,539,706
52-wk High
CHF273.00
52-wk Low
CHF226.10

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.98
Market Cap(Mil.): CHF207,676.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.39

Financials

  Industry Sector
P/E (TTM): -- 32.07 15.47
EPS (TTM): -- -- --
ROI: -- 15.07 33.71
ROE: -- 16.57 16.38

BRIEF-Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)

* IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE

Dec 11 2017

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday.

Dec 11 2017

UPDATE 2-Roche: Tecentriq cocktail slows kidney cancer progression

* Swiss drugmaker aims to expand drug's indications (Adds analyst comment, shares)

Dec 11 2017

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH, Dec 11 Swiss drugmaker Roche said on Monday that a combination of its Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients.

Dec 11 2017

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Dec 10 2017

Gilead's new drug keeps 56 pct of lymphoma trial patients alive

Dec 10 More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Dec 10 2017

Roche lymphoma drug drives high remission rate, longer survival: study

An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday.

Dec 10 2017

Roche lymphoma drug drives high remission rate, longer survival-study

Dec 10 An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday.

Dec 10 2017

Roche chairman confident new drugs will offset patent losses: report

ZURICH Roche Chairman Christoph Franz remains confident the Swiss drugmaker can offset revenue declines from patent expired medicines with new drugs, according to an interview published on Sunday in the Swiss newspaper NZZ am Sonntag.

Dec 10 2017

Roche chairman confident new drugs will offset patent losses -- report

ZURICH, Dec 10 Roche Chairman Christoph Franz remains confident the Swiss drugmaker can offset revenue declines from patent expired medicines with new drugs, according to an interview published on Sunday in the Swiss newspaper NZZ am Sonntag.

Dec 10 2017

Earnings vs. Estimates